Company intelligence / Profile preview

Arbormentis

United States

Ownership: Private
Development stage: Other

Overview

Arbormentis had a preclinical program focused on novel psilocybin and derivatives to promote neural plasticity for CNS disease; a licensing agreement granted Relmada Therapeutics rights to the program for ex-Asia regions[1][6][9]. No clinical data reported as of the licensing (mid-2021).

Therapeutic areas: NeurologyPsychiatry
Modalities: Small moleculePsychedelic derivative
Industry: Biotech

Partnerships

Relmada Therapeutics (licensed development and commercialization rights ex-Asia)[1]

Beyond the preview

Go deeper on Arbormentis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arbormentis.

Explore the full profile